Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Jan;12(1):105-112.
doi: 10.1111/chd.12413. Epub 2016 Sep 29.

A population-based analysis of mortality in patients with Turner syndrome and hypoplastic left heart syndrome using the Texas Birth Defects Registry

Diego A Lara  1 , Mary K Ethen  2 , Mark A Canfield  2 , Wendy N Nembhard  3 , Shaine A Morris  1
Affiliations
Comparative Study

A population-based analysis of mortality in patients with Turner syndrome and hypoplastic left heart syndrome using the Texas Birth Defects Registry

Diego A Lara et al. Congenit Heart Dis. 2017 Jan.

Abstract

Background: Hypoplastic left heart syndrome (HLHS) is strongly associated with Turner syndrome (TS); outcome data when these conditions coexist is sparse. We aimed to investigate long-term survival and causes of death in this population.

Methods: The Texas Birth Defects Registry was queried for all live born infants with HLHS during 1999-2007. We used Kaplan-Meier and Cox regression analyses to compare survival among patients with HLHS with TS (HLHS/TS+) to patients who had HLHS without genetic disorders or extracardiac birth defects (HLHS/TS-).

Results: Of the 542 patients with HLHS, 11 had TS (2.0%), 71 had other extracardiac birth defects or genetic disorders, and 463 had neither. The median follow-up time was 4.2 y (interquartile range [IQR] 2.1-6.5). Comparing those with HLHS/TS+ to HLHS/TS-, 100% versus 35% were female (P < .001), and median birth weight was 2140 g (IQR 1809-2650) versus 3196 g (IQR 2807-3540, P < .001). Neonatal mortality was 36% in HLHS/TS+ versus 27% in HLHS/TS- (log rank = 0.431). Ten of the 11 TS+ patients died during the study period for cumulative mortality of 91% versus 50% (hazard ratio (HR) for TS+: 2.90, 95% CI 1.53-5.48). Six patients died prior to surgery, 5 underwent Stage 1 palliation (S1P), 3 died after S1P, 2 survived past S2P, and one of these died at age 19 mo. The underlying cause of death was listed as congenital heart disease on all the death certificates of HLHS/TS+ patients. In multivariable analysis controlling for low birth weight (<2500 g), TS remained associated with significantly increased cumulative mortality, although females without TS had higher mortality than males (HR for TS+ versus males: 2.42, 95% CI 1.24-4.73; HR for TS- females versus males: 1.41, 95% CI 1.08-1.83).

Conclusion: TS with HLHS is associated with significant mortality. The increased mortality in females without documented TS calls to question if TS is undetected in a portion of females with HLHS.

Keywords: Turner syndrome; female; gender; hypoplastic left heart syndrome; population; sex.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

None.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier survival curve for infants with hypoplastic left heart syndrome, with and without Turner syndrome, Texas, 1999–2007
FIGURE 2
FIGURE 2
Kaplan–Meier survival curve for hypoplastic left heart syndrome in males, females without Turner syndrome, and female with Turner syndrome, Texas, 1999–2007
FIGURE 3
FIGURE 3
Timing of death in patients with hypoplastic left heart syndrome and Turner syndrome
FIGURE 4
FIGURE 4
Kaplan–Meier survival curve for infants with hypoplastic left heart syndrome with and without Turner syndrome who have undergone Stage I palliation, Texas 1999–2007
See this image and copyright information in PMC

References

    1. Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab. 2007;92(1):10–25. - PubMed
    1. Chacko E, Graber E, Regelmann MO, Wallach E, Costin G, Rapaport R. Update on Turner and Noonan syndromes. Endocrinol Metab Clin North Am. 2012;41(4):713–734. - PubMed
    1. Bondy CA. Heart disease in Turner syndrome. Minerva Endocrinol. 2007;32(4):245–261. - PubMed
    1. Gutmark-Little I, Hor KN, Cnota J, Gottliebson WM, Backeljauw PF. Partial anomalous pulmonary venous return is common in Turner syndrome. J Pediatr Endocrinol Metab. 2012;25(5–6):435–440. - PubMed
    1. Ho VB, Bakalov VK, Cooley M, et al. Major vascular anomalies in Turner syndrome: prevalence and magnetic resonance angiographic features. Circulation. 2004;110(12):1694–1700. - PubMed

Publication types

MeSH terms